SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $34,750.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $6.95, for a total transaction of $34,750.00. Following the transaction, the chief technology officer owned 187,171 shares in the company, valued at $1,300,838.45. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH opened at $7.71 on Friday. The company has a current ratio of 2.69, a quick ratio of 1.90 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 12 month low of $2.96 and a 12 month high of $7.86. The company has a market capitalization of $646.79 million, a price-to-earnings ratio of -6.70 and a beta of 0.96. The firm’s 50-day moving average is $5.63 and its 200 day moving average is $5.15.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright boosted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. BTIG Research upped their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of SOPHiA GENETICS

Large investors have recently modified their holdings of the company. Silverberg Bernstein Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares in the last quarter. Principal Financial Group Inc. increased its holdings in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS during the first quarter valued at approximately $50,000. Finally, Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the third quarter worth approximately $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.